FIRST LINE OF TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHILDREN AND ADOLESCENTS IN THE REPUBLIC OF BELARUS
https://doi.org/10.29235/1814-6023-2018-15-3-306-314
Abstract
Survival was cardinally increased after introducing Imatinib into the first line of therapy of chronic myeloid leukemia (CML) in children. However primary or second resistance was observed in 20–30 % of patients. For the purpose of detection of prognostic factors, a minimal residual disease was monitored in 22 patients at an age of 0–17 years. Furthermore, different variants of BCR/ABL transcript were identified. The results showed that patients with an early major molecular response and a b3a2 variant of the BCR/ABL transcript had significantly better results of treatment. In conclusion, a regular monitoring of a deep molecular response and a further correction of therapy allowed one to increase long-term overall survival in children with CML.
About the Author
M. V. Borisevich
Republican Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Belarus
Marina V. Borisevich – deputy director for organizational and methodological work
43, Frunzenskaya Str., v. Borovliany, 223053, Minsk Region
References
1. Nikulina O. V., Tsaur G. A., Riger T. O., Yakovleva Yu. A., Demina A. S., Semenikhina E. R., Spil’nik T. V., Savel’ev L. I., Fechina L. G. Diagnostic strategy for detection of typical and atypical BCR-ABL fusion gene transcripts in chronic myeloid leukemia. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika [Clinical Oncohematology. Basic Research and Clinical Practice], 2015, vol. 8, no. 2, pp. 161–168 (in Russian).
2. Falchi L., Kantarjian H. M., Wang X., Verma D., Quintás-Cardama A., O’Brien S., Jabbour E. J., Ravandi-Kashani F., Borthakur G., Garcia-Manero G., Verstovsek S., Burger J. A., Luthra R., Cortes J. E. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. American Journal of Hematology, 2013, vol. 88, no. 12, pp. 1024–1029. https://doi.org/10.1002/ajh.23560
3. Gabert J., Beillard E., van der Velden V. H. J., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J. M., Cavé H., Pane F., Aerts J. L. E., De Micheli D., Thirion X., Pradel V., González M., Viehmann S., Malec M., Saglio G., van Dongen J. J. M. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe against Cancer Program. Leukemia, 2003, vol. 17, no. 12, pp. 2318–2357. https://doi.org/10.1038/sj.leu.2403135
4. Baccarani M., Deininger M. W., Rosti G., Hochhaus A., Soverini S., Apperley J. F., Cervantes F., Clark R. E., Cortes J. E., Guilhot F., Hjorth-Hansen H., Hughes T. P., Kantarjian H. M., Kim D.-W., Larson R. A., Lipton J. H., Mahon F.-X., Martinelli G., Mayer J., Muller M. C., Niederwieser D., Pane F., Radich J. P., Rousselot P., Saglio G., Saussele S., Schiffer C., Silver R., Simonsson B., Steegmann J.-L., Goldman J. M., Hehlmann R. European Leukemia Net recommendations for the management of chronic myeloid leukemia. Blood, 2013, vol. 122, no. 6, pp. 872–884. https://doi.org/10.1182/blood-2013-05-501569
5. Iacobucci I., Saglio G., Rosti G., Testoni N., Pane F., Amabile M., Poerio A., Soverini S., Bassi S., Cilloni D., Bassan R., Breccia M., Lauria F., Izzo B., Merante S., Frassoni F., Paolini S., Montefusco E., Baccarani M., Martinelli G. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in Imatinib-treated chronic myeloid leukemia patients. Clinical Cancer Research, 2006, vol. 12, no. 10, pp. 3037–3042. https:// doi.org/10.1158/1078-0432.ccr-05-2574
6. Cortes J., Talpaz M., O’Brien S., Jones D., Luthra R., Shan J., Giles F., Faderl S., Verstovsek S., Garcia-Manero G., Rios M. B., Kantarjian H. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with Imatinib Mesylate. Clinical Cancer Research, 2005, vol. 11, no. 9, pp. 3425–3432. https://doi.org/10.1158/1078-0432.ccr-04-2139
7. Kutsev S., Vel’chenko M. The role of BCR-ABL gene mutation analysis in the optimization of target therapy of chronic myeloid leukemia. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika [Clinical oncohematology. basic research and clinical practice], 2008, vol. 1, no. 3, pp. 190–199 (in Russian).
8. Coebergh J. W. W., Reedijk A. M. J., de Vries E., Martos C., Jakab Z., Steliarova-Foucher E., Kamps W. A. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System Project. European Journal of Cancer, 2006, vol. 42, no. 13, pp. 2019–2036. https://doi.org/10.1016/j. ejca.2006.06.005
9. Suttorp M., Tabea Tauer J., Millot F. Chronic myeloid leukemia in children: diagnostics and management. Third midsummer meeting on pediatric hematology and oncology, 10–12 June, Liberec. Prague, 2011, pp. 12–13.
10. Pavlu J., Szydlo R. M., Goldman J. M., Apperley J. F. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood, 2011, vol. 117, no. 3, pp. 755–763. https://doi.org/10.1182/blood-2010-08-301341
11. Mahon F.-X., Réa D., Guilhot J., Huguet F., Nicolini F., Legros L., Charbonnier A., Guerci A., Varet B., Etienne G., Reiffers J., Rousselot P. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncology, 2010, vol. 11, no. 11, pp. 1029–1035. https://doi.org/10.1016/s1470-2045(10)70233-3
12. Suttorp M., Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology, 2010, vol. 2010, no. 1, pp. 368–376. https://doi.org/10.1182/asheducation-2010.1.368
13. Wei G., Rafiyath S., Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Journal of Hematology and Oncology, 2010, vol. 3, no. 1, art. 47. https://doi.org/10.1186/1756-8722-3-47
14. Suttorp M., Claviez A., Bader P., Peters C., Gadner H., Ebell W., Dilloo D., Kremens B., Kabisch H., Führer M., Zintl F., Göbel U., Klingebiel T. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-Paed I. Klinische Pädiatrie, 2009, vol. 221, no. 6, pp. 351–357. https://doi.org/10.1055/s-0029-1239529
15. Gambacorti-Passerini C., Gunby R., Piazza R., Galietta A., Rostagno R., Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncology, 2003, vol. 4, no. 2, pp. 75–85. https:// doi.org/10.1016/s1470-2045(03)00979-3
16. Kreil S., Mueller M. C., Hanfstein B., La Rosee P., Lahaye T., Hehlmann R., Hochhaus A. Management and clinical outcome of CML patients after imatinib resistance associated with ABL kinase domain mutations. Blood, vol. 102, no. 11, p. 71A.
17. Shah N., Sawyers C. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemia. Oncogene, 2003, vol. 22, no. 47, pp. 7389–7395. https://doi.org/10.1038/sj.onc.1206942
18. Al-Ali H., Heinrich M. Ch., Lange T., Krahl R., Mueller M., Müller C., Niederwieser D., Druker B. J., Deininger M. W. N. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematology Journal, 2004, vol. 5, no. 1, pp. 55–60. https://doi.org/10.1038/ sj.thj.6200319
19. Hochhaus A., La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia, 2004, vol. 18, no. 8, pp. 1321–1331. https://doi.org/10.1038/sj.leu.2403426
20. Branford S. Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology, 2007, vol. 2007, no. 1, pp. 376–383. https://doi.org/10.1182/asheducation-2007.1.376
21. Adler R., Viehmann S., Kuhlisch S., Martiniak Y., Harbott S. R. J., Suttorp M. Correlation of BCR/ABL transcript variants with patients characteristics in childhood chronic myeloid leukaemia. European Journal of Haematology, 2009, vol. 82, no. 2, pp. 112–118. https://doi.org/10.1111/j.1600-0609.2008.01170.x
Review
For citations:
Borisevich M.V. FIRST LINE OF TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHILDREN AND ADOLESCENTS IN THE REPUBLIC OF BELARUS. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2018;15(3):306-314. (In Russ.) https://doi.org/10.29235/1814-6023-2018-15-3-306-314
Views: 615
Email this article 